References
Besenval M, Leray F, Delgado FM, Merle S, Krikorian A, et al. Navelbine (vinorelbine) tolerance in non-small-cell lung cancer. In Pierre Fabre Oncologie (Eds) Navelbine (vinorelbine). Update and new trends, pp. 185–194, John Libbey Eurotext, Montrouge, 1991
Hansen HH. Chemotherapy of small-cell carcinoma: a review. Quarterly Journal of Medicine 63: 275–282, 1987
Izzo J, Cvitkovic E, Toussaint G, Chabot F, et al. High activity and dose intensity (DI) relationship in advanced breast cancer (ABC) with continuous infusion (CIV) of navelbine. Proceedings of the Second Interface of Clinical and Laboratory Responses to Antitumour Drugs: Drugs and Microtubules, p. S6, Marseilles, 2–4 April 1992
Østerlind K, Andersen PK. Prognostic factors in small-cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Research 46: 4189–4194, 1986
Quoix E, Dietermann A, Charbonneau J, Boutin C, Meurice JC, et al. La chimiothérapie comportant du cisplatine est-elle utile dans le cancer bronchique non microcellulaire au stade IV? Résultats d’une étude randomisée. Bulletin du Cancer 78: 341–346, 1991
Rapp E, Pater JL, Willan A, Cormier Y, Murray N, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer — report of a Canadian multicenter randomized trial. Journal of Clinical Oncology 6: 633–641, 1988
Woods RL, Williams CJ, Levi J, Page J, Bell D, et al. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small-cell lung cancer. British Journal of Cancer 61: 608–611, 1990
Rights and permissions
About this article
Cite this article
Round-Table Discussion. Drugs 44 (Suppl 4), 66–69 (1992). https://doi.org/10.2165/00003495-199200444-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199200444-00008